INZY实时信号 | 通过Getagraph.com最大化利润

出售 116214 min ago

@ $5.52

发出时间: 14 Feb 2024 @ 22:33

回报率: -14.13%

上一信号: Feb 13 - 22:30

上一信号: 购买

回报率: -1.87 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	323 223
平均成交量	689 424
市值	292.80M
EPS	$0 ( 2024-03-27 )
下一个收益日期	( $-0.350 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.46
ATR14	$0.00500 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Treco Douglas A	Sell	25 000	Restricted Stock Units
2024-04-01	Treco Douglas A	Buy	25 000	Common Stock
2024-04-02	Treco Douglas A	Sell	7 523	Common Stock
2024-03-28	Winton Matthew	Buy	3 188	Common Stock
2024-03-13	Winton Matthew	Buy	175 000	Stock Option (right to buy)

INSIDER POWER
97.89
Last 96 transactions
Buy: 18 900 467 \| Sell: 34 205 433

音量相关性

長: 0.06 (neutral)

短: 0.99 (very strong)

Signal:(59.135) Expect same movement, but be aware

Inozyme Pharma, Inc. 相关性

10 最正相关
NAUT	0.951
SVFAU	0.95
AMTBB	0.945
WINA	0.943
TZPSU	0.941
BIOT	0.94
COCO	0.937
TZPS	0.937
SVFA	0.935
LMB	0.934

10 最负相关
IPA	-0.947
WABC	-0.947
ISTR	-0.945
AROW	-0.945
BMRC	-0.945
BWB	-0.941
FVCB	-0.939
NFBK	-0.938
FLIC	-0.937
CVBF	-0.937

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Inozyme Pharma, Inc. 相关性 - 货币/商品

-0.29
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.22
( neutral )

-0.17
( neutral )

Inozyme Pharma, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.29M (0.00 %)
EPS:	$-1.370

FY	2023
营收:	$0
毛利润:	$-1.29M (0.00 %)
EPS:	$-1.370

FY	2022
营收:	$0
毛利润:	$-1.18M (0.00 %)
EPS:	$-1.730

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.40

Financial Reports:

No articles found.

Inozyme Pharma, Inc.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.